Secondary end point analysis revealed that GLP-1 RA use was associated with significant reductions in all-cause mortality (HR, 0.57; 95% CI, 0.37-0.82; P = .009; E-value = 2.90), new-onset HF (HR, 0.69; 95% CI, 0.54-0.90; P = .005; E-value = 2.26), decompensated HF (HR, 0.60; 95% CI, 0.43-0.84; P = .002; E-value = 2.72), AKI or progression to ESKD (HR, 0.73; 95% CI, 0.57-0.92; P = .01; E-value = 2.08), and other CV events (HR, 0.76; 95% CI, 0.62-0.93; P = .009; E-value = 1.96) (Table 2). The gene discussed is GLP1R; the disease is acute kidney injury.